Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
This Phase 1b/2 study is designed to assess the safety and efficacy of ibrutinib in combination with lenalidomide and rituximab in subjects with relapsed/refractory Diffuse Large B-Cell Lymphoma (DLBCL) not eligible for transplant.
Inclusion criteria
- Relapsed Diffuse Large B-Cell Lymphoma,Refractory Diffuse large B-cell lymphoma